Clinical efficacy of Bucillamine for childhood rheumatic disease

• Published in: Ensho Vol. 14; no. 1; pp. 61 - 65
• Main Authors: Nagata, Masato, Satou, Tatsuya, Tatsuzawa, Osamu, Koike, Yuichi
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society of Inflammation and Regeneration 1994
• Subjects: Bucillamine; disease-modifying antirheumatic drugs (DMARDs); juvenile rheumatoid arthritis (JRA)
• ISSN: 0389-4290; 1884-4006
• DOI: 10.2492/jsir1981.14.61

Bucillamine (1.6-3.0 mg/kg/day) was administered to 9 children with rheumatic diseases resistant to aspirin. The usefulness was evaluated based on improvement in the functional impairments and other symptoms at 12 weeks and 1 year after administration. The results disclosed evidence that clinical improvement with decreased numbers of painfull joints in 7 cases (5 cases with polyarticular type JRA, 1 case with juvenile chronic arthritis and 1 case with spondyloarthropathy) . Stomatitis was found in 2 cases and proteinurea in 1 case as adverse effects. Bucillamine was useful for children with rheumatic diseases to whom nonsteroidal antiinflammatory drug was ineffective.